Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.65 (market cap $7.77B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 16.5× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PDBC | VRTX | |
|---|---|---|
Market Cap | $7.77B | $128.16B |
Volume | 4,055,996 | 806,603 |
52-Week High | $20.10 | $557.96 |
52-Week Low | $13.16 | $407.37 |
Typical Hold Time | 56 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC trades at $19.41, down 0.26% with neutral technical signals from moving averages and oscillators. The ETF has demonstrated strong performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodity strength amid geopolitical tensions. Recent institutional activity shows mixed sentiment with significant short interest growth of 215.4% in September offset by new institutional positions from firms like Arlington Capital and Advisortrust Partners.
The commodity ETF faces a complex outlook with potential upside from ongoing geopolitical tensions and defensive portfolio rotation, but risks include the sharp increase in short interest and commodity market volatility. Analyst sentiment remains cautiously optimistic given the fund's strong 2026 performance and defensive characteristics in uncertain markets.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
